カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界のヒトVEGF抗体市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Human VEGF Antibody Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22MY8846）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22MY8846
■ 発行日：2022年5月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：121
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界のヒトVEGF抗体市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

ヒトVEGF抗体市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のヒトVEGF抗体の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

ヒトVEGF抗体市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・ウサギ、ネズミ、ヤギ、その他

用途別セグメントは次のように区分されます。
・研究室、病院、その他

世界のヒトVEGF抗体市場の主要な市場プレーヤーは以下のとおりです。
・Thermo Fisher、MilliporeSigma、Santa Cruz Biotechnology、Abcam、R&D Systems、Novus Biologicals、Abnova、ImmunoStar、OriGene、LifeSpan Biosciences、Sino Biological、Bio-Rad、BioLegend、Rockland Immunochemicals、Agrisera、Boster、ProMab、Creative Biomart、Enzo Life Sciences、Bon Opus Biosciences、Absolute Antibody、US Biological

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、ヒトVEGF抗体製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なヒトVEGF抗体メーカーの企業概要、2019年～2022年までのヒトVEGF抗体の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なヒトVEGF抗体メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別ヒトVEGF抗体の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのヒトVEGF抗体の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのヒトVEGF抗体市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびヒトVEGF抗体の産業チェーンを掲載しています。
・第13、14、15章では、ヒトVEGF抗体の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Thermo Fisher、MilliporeSigma、Santa Cruz Biotechnology、Abcam、R&D Systems、Novus Biologicals、Abnova、ImmunoStar、OriGene、LifeSpan Biosciences、Sino Biological、Bio-Rad、BioLegend、Rockland Immunochemicals、Agrisera、Boster、ProMab、Creative Biomart、Enzo Life Sciences、Bon Opus Biosciences、Absolute Antibody、US Biological
・メーカー別市場シェア
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：ウサギ、ネズミ、ヤギ、その他
・用途別分析2017年-2028年：研究室、病院、その他
・ヒトVEGF抗体の北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ
・ヒトVEGF抗体のヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア
・ヒトVEGF抗体のアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア
・ヒトVEGF抗体の南米市場規模2017年-2028年：ブラジル、アルゼンチン
・ヒトVEGF抗体の中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Human VEGF Antibody market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Human VEGF Antibody market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Laboratory accounting for % of the Human VEGF Antibody global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Rabbit segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Human VEGF Antibody include Thermo Fisher, MilliporeSigma, Santa Cruz Biotechnology, Abcam, and R&D Systems, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Human VEGF Antibody market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Rabbit
Mouse
Goat
Others
Market segment by Application can be divided into
Laboratory
Hospital
Others
The key market players for global Human VEGF Antibody market are listed below:
Thermo Fisher
MilliporeSigma
Santa Cruz Biotechnology
Abcam
R&D Systems
Novus Biologicals
Abnova
ImmunoStar
OriGene
LifeSpan Biosciences
Sino Biological
Bio-Rad
BioLegend
Rockland Immunochemicals
Agrisera
Boster
ProMab
Creative Biomart
Enzo Life Sciences
Bon Opus Biosciences
Absolute Antibody
US Biological
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Human VEGF Antibody product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Human VEGF Antibody, with price, sales, revenue and global market share of Human VEGF Antibody from 2019 to 2022.
Chapter 3, the Human VEGF Antibody competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human VEGF Antibody breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Human VEGF Antibody market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Human VEGF Antibody.
Chapter 13, 14, and 15, to describe Human VEGF Antibody sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Human VEGF Antibody Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Human VEGF Antibody Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Rabbit
1.2.3 Mouse
1.2.4 Goat
1.2.5 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Human VEGF Antibody Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Laboratory
1.3.3 Hospital
1.3.4 Others
1.4 Global Human VEGF Antibody Market Size & Forecast
1.4.1 Global Human VEGF Antibody Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Human VEGF Antibody Sales in Volume (2017-2028)
1.4.3 Global Human VEGF Antibody Price (2017-2028)
1.5 Global Human VEGF Antibody Production Capacity Analysis
1.5.1 Global Human VEGF Antibody Total Production Capacity (2017-2028)
1.5.2 Global Human VEGF Antibody Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Human VEGF Antibody Market Drivers
1.6.2 Human VEGF Antibody Market Restraints
1.6.3 Human VEGF Antibody Trends Analysis
2 Manufacturers Profiles
2.1 Thermo Fisher
2.1.1 Thermo Fisher Details
2.1.2 Thermo Fisher Major Business
2.1.3 Thermo Fisher Human VEGF Antibody Product and Services
2.1.4 Thermo Fisher Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 MilliporeSigma
2.2.1 MilliporeSigma Details
2.2.2 MilliporeSigma Major Business
2.2.3 MilliporeSigma Human VEGF Antibody Product and Services
2.2.4 MilliporeSigma Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Santa Cruz Biotechnology
2.3.1 Santa Cruz Biotechnology Details
2.3.2 Santa Cruz Biotechnology Major Business
2.3.3 Santa Cruz Biotechnology Human VEGF Antibody Product and Services
2.3.4 Santa Cruz Biotechnology Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Abcam
2.4.1 Abcam Details
2.4.2 Abcam Major Business
2.4.3 Abcam Human VEGF Antibody Product and Services
2.4.4 Abcam Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 R&D Systems
2.5.1 R&D Systems Details
2.5.2 R&D Systems Major Business
2.5.3 R&D Systems Human VEGF Antibody Product and Services
2.5.4 R&D Systems Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Novus Biologicals
2.6.1 Novus Biologicals Details
2.6.2 Novus Biologicals Major Business
2.6.3 Novus Biologicals Human VEGF Antibody Product and Services
2.6.4 Novus Biologicals Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Abnova
2.7.1 Abnova Details
2.7.2 Abnova Major Business
2.7.3 Abnova Human VEGF Antibody Product and Services
2.7.4 Abnova Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 ImmunoStar
2.8.1 ImmunoStar Details
2.8.2 ImmunoStar Major Business
2.8.3 ImmunoStar Human VEGF Antibody Product and Services
2.8.4 ImmunoStar Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 OriGene
2.9.1 OriGene Details
2.9.2 OriGene Major Business
2.9.3 OriGene Human VEGF Antibody Product and Services
2.9.4 OriGene Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 LifeSpan Biosciences
2.10.1 LifeSpan Biosciences Details
2.10.2 LifeSpan Biosciences Major Business
2.10.3 LifeSpan Biosciences Human VEGF Antibody Product and Services
2.10.4 LifeSpan Biosciences Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Sino Biological
2.11.1 Sino Biological Details
2.11.2 Sino Biological Major Business
2.11.3 Sino Biological Human VEGF Antibody Product and Services
2.11.4 Sino Biological Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Bio-Rad
2.12.1 Bio-Rad Details
2.12.2 Bio-Rad Major Business
2.12.3 Bio-Rad Human VEGF Antibody Product and Services
2.12.4 Bio-Rad Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 BioLegend
2.13.1 BioLegend Details
2.13.2 BioLegend Major Business
2.13.3 BioLegend Human VEGF Antibody Product and Services
2.13.4 BioLegend Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Rockland Immunochemicals
2.14.1 Rockland Immunochemicals Details
2.14.2 Rockland Immunochemicals Major Business
2.14.3 Rockland Immunochemicals Human VEGF Antibody Product and Services
2.14.4 Rockland Immunochemicals Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 Agrisera
2.15.1 Agrisera Details
2.15.2 Agrisera Major Business
2.15.3 Agrisera Human VEGF Antibody Product and Services
2.15.4 Agrisera Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16 Boster
2.16.1 Boster Details
2.16.2 Boster Major Business
2.16.3 Boster Human VEGF Antibody Product and Services
2.16.4 Boster Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17 ProMab
2.17.1 ProMab Details
2.17.2 ProMab Major Business
2.17.3 ProMab Human VEGF Antibody Product and Services
2.17.4 ProMab Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18 Creative Biomart
2.18.1 Creative Biomart Details
2.18.2 Creative Biomart Major Business
2.18.3 Creative Biomart Human VEGF Antibody Product and Services
2.18.4 Creative Biomart Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19 Enzo Life Sciences
2.19.1 Enzo Life Sciences Details
2.19.2 Enzo Life Sciences Major Business
2.19.3 Enzo Life Sciences Human VEGF Antibody Product and Services
2.19.4 Enzo Life Sciences Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.20 Bon Opus Biosciences
2.20.1 Bon Opus Biosciences Details
2.20.2 Bon Opus Biosciences Major Business
2.20.3 Bon Opus Biosciences Human VEGF Antibody Product and Services
2.20.4 Bon Opus Biosciences Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.21 Absolute Antibody
2.21.1 Absolute Antibody Details
2.21.2 Absolute Antibody Major Business
2.21.3 Absolute Antibody Human VEGF Antibody Product and Services
2.21.4 Absolute Antibody Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.22 US Biological
2.22.1 US Biological Details
2.22.2 US Biological Major Business
2.22.3 US Biological Human VEGF Antibody Product and Services
2.22.4 US Biological Human VEGF Antibody Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Human VEGF Antibody Breakdown Data by Manufacturer
3.1 Global Human VEGF Antibody Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Human VEGF Antibody Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Human VEGF Antibody
3.4 Market Concentration Rate
3.4.1 Top 3 Human VEGF Antibody Manufacturer Market Share in 2021
3.4.2 Top 6 Human VEGF Antibody Manufacturer Market Share in 2021
3.5 Global Human VEGF Antibody Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Human VEGF Antibody Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Human VEGF Antibody Market Size by Region
4.1.1 Global Human VEGF Antibody Sales in Volume by Region (2017-2028)
4.1.2 Global Human VEGF Antibody Revenue by Region (2017-2028)
4.2 North America Human VEGF Antibody Revenue (2017-2028)
4.3 Europe Human VEGF Antibody Revenue (2017-2028)
4.4 Asia-Pacific Human VEGF Antibody Revenue (2017-2028)
4.5 South America Human VEGF Antibody Revenue (2017-2028)
4.6 Middle East and Africa Human VEGF Antibody Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Human VEGF Antibody Sales in Volume by Type (2017-2028)
5.2 Global Human VEGF Antibody Revenue by Type (2017-2028)
5.3 Global Human VEGF Antibody Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Human VEGF Antibody Sales in Volume by Application (2017-2028)
6.2 Global Human VEGF Antibody Revenue by Application (2017-2028)
6.3 Global Human VEGF Antibody Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Human VEGF Antibody Sales by Type (2017-2028)
7.2 North America Human VEGF Antibody Sales by Application (2017-2028)
7.3 North America Human VEGF Antibody Market Size by Country
7.3.1 North America Human VEGF Antibody Sales in Volume by Country (2017-2028)
7.3.2 North America Human VEGF Antibody Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Human VEGF Antibody Sales by Type (2017-2028)
8.2 Europe Human VEGF Antibody Sales by Application (2017-2028)
8.3 Europe Human VEGF Antibody Market Size by Country
8.3.1 Europe Human VEGF Antibody Sales in Volume by Country (2017-2028)
8.3.2 Europe Human VEGF Antibody Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Human VEGF Antibody Sales by Type (2017-2028)
9.2 Asia-Pacific Human VEGF Antibody Sales by Application (2017-2028)
9.3 Asia-Pacific Human VEGF Antibody Market Size by Region
9.3.1 Asia-Pacific Human VEGF Antibody Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Human VEGF Antibody Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Human VEGF Antibody Sales by Type (2017-2028)
10.2 South America Human VEGF Antibody Sales by Application (2017-2028)
10.3 South America Human VEGF Antibody Market Size by Country
10.3.1 South America Human VEGF Antibody Sales in Volume by Country (2017-2028)
10.3.2 South America Human VEGF Antibody Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Human VEGF Antibody Sales by Type (2017-2028)
11.2 Middle East & Africa Human VEGF Antibody Sales by Application (2017-2028)
11.3 Middle East & Africa Human VEGF Antibody Market Size by Country
11.3.1 Middle East & Africa Human VEGF Antibody Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Human VEGF Antibody Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Human VEGF Antibody and Key Manufacturers
12.2 Manufacturing Costs Percentage of Human VEGF Antibody
12.3 Human VEGF Antibody Production Process
12.4 Human VEGF Antibody Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Human VEGF Antibody Typical Distributors
13.3 Human VEGF Antibody Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のVEGF抗体市場2022年：市場規模予測（～2028年）
  • 世界のヒトアディポネクチン抗体市場2022年：市場規模予測（～2028年）
  • 世界のヒト抗バーシカン抗体市場2022年：市場規模予測（～2028年）
  • 世界のヒトインテグリンBeta3抗体市場2022年：市場規模予測（～2028年）
  • 世界のPD-1＆PD-L1モノクローナル抗体市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22MY8846 )"世界のヒトVEGF抗体市場2022年：市場規模予測（～2028年）" (英文：Global Human VEGF Antibody Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。